Catalent (NYSE:CTLT) Announces Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Catalent (NYSE:CTLT) posted its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18), Briefing.com reports. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Catalent’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.10) earnings per share.

Catalent Stock Up 2.5 %

Shares of NYSE:CTLT traded up $1.48 during trading on Wednesday, hitting $59.96. The stock had a trading volume of 3,536,560 shares, compared to its average volume of 2,046,123. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. Catalent has a 12 month low of $32.38 and a 12 month high of $61.20. The company has a market capitalization of $10.88 billion, a PE ratio of -10.65, a PEG ratio of 2.06 and a beta of 1.16. The firm’s fifty day moving average is $60.03 and its 200 day moving average is $58.02.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com initiated coverage on Catalent in a research note on Saturday, October 12th. They set a “hold” rating for the company. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $59.83.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.31% of the stock is currently owned by corporate insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.